Tami Tillotson Martin Form 3 SUPERNUS PHARMACEUTICALS / Tami Tillotson Martin ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Martin Tami Tillotson

(Last) (First) (Middle)

C/O SUPERNUS PHARMACEUTICALS, INC.

1550 EAST GUDE DRIVE

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/21/2020

3. Issuer Name and Ticker or Trading Symbol
SUPERNUS PHARMACEUTICALS, INC. [ SUPN ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Sr. V.P., Regulatory Affairs

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	85,279	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	(1)	02/05/2023	Common Stock	10,000	7.9	D
Employee Stock Option (Right to Buy)	(2)	01/21/2024	Common Stock	8,000	9.24	D
Employee Stock Option (Right to Buy)	(3)	03/03/2025	Common Stock	25,000	9.13	D
Employee Stock Option (Right to Buy)	(4)	03/01/2026	Common Stock	12,500	12.98	D
Employee Stock Option (Right to Buy)	(5)	02/24/2027	Common Stock	13,500	25.3	D
Employee Stock Option (Right to Buy)	(6)	02/14/2028	Common Stock	12,000	39.4	D
Employee Stock Option (Right to Buy)	(7)	02/22/2029	Common Stock	20,000	36.75	D

Explanation of Responses:

1. The option vests in four equal annual installments beginning on February 5, 2014.

2. The option vests in four equal annual installments beginning on January 21, 2015.

3. The option vests in four equal annual installments beginning on March 3, 2016.

4. The option vests in four equal annual installments beginning on March 1, 2017.

5. The option vests in four equal annual installments beginning on February 24, 2018.

6. The option vests in four equal annual installments beginning on February 14, 2019.

7. The option vests in four equal annual installments beginning on February 22, 2020.

Remarks:

Exhibit 24 Power of Attorney

	/s/ Gregory S. Patrick, as attorney-in-fact	02/25/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.